Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

NCT04405622 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Metastatic Nasopharyngeal Carcinoma
Chemotherapy Effect
Immunotherapy

Interventions

DRUG: Toripalimab plus gemcitabine

Sponsor

Sun Yat-sen University